secwatch.observer — SEC 8-K summary
======================================

Issuer:     Agentix Corp. (AGTX)
CIK:        0001603345
Form:       8-K
Filed at:   2021-12-21T23:59:59+00:00
Accession:  0001477932-21-009384
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agentix and RTI announce worldwide exclusive license for NAFLD, NASH, T2D, obesity candidates
--------------------------------------------------------------------------------

- License covers RTI small-molecule candidates for NAFLD, NASH, T2D, and obesity.
- Agentix must complete Phase I trials by Jan 15, 2023; Phase II by Oct 2025; Phase III by Oct 2028.
- Agentix plans to file IND with FDA in ~12 months; RTI to assist with IND-enabling toxicology and GMP manufacturing.
- No financial terms disclosed; pre-clinical data show efficacy in animal models of metabolic diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1603345/000147793221009384/0001477932-21-009384-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1603345/000147793221009384/agtx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-21-009384

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer